PHARMA JAPAN THE ONLY ENGLISH DRUG NEWS SITE IN JAPAN

Friday, April.20.2018
User ID
PASSWORD
  • TOP NEWS|
  • REGULATORY|
  • BUSINESS|
  • ORGANIZATION|
  • ACADEMIA
Home>ORGANIZATION

ORGANIZATION

  • Astellas Becomes 1st Japan Maker to Join PhRMA Leadership

    February 14.2018
  • Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules

    February 9.2018
  • “Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura

    February 8.2018
  • Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA

    January 30.2018
  • Japan Pharma Leader Says Pricing Overhaul Would Not Expand Drug Lag

    January 18.2018
  • Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief

    January 15.2018
  • Pharma Leaders Air Bleak Outlook on New PMP Scheme at New Year’s Reception

    January 10.2018
  • JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief

    December 22.2017
  • Continued Discussions Needed for PMP-Eligible Products, Company Criteria: FPMAJ/JPMA

    December 22.2017
  • PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences

    December 21.2017
< Prev 1 2 3 4 5 6 7 8 9 10 Next >

Commentary

With Drug Price Cuts Done, MHLW Now Running Ministry-Wide Initiative to Shave Prescriptions

Lexicon

G1/G2 Rule:
G1/G2ルール

The Column

It Is Thumbs Up for Cell Therapy in Japan

Archives

Biosimilar Use Essential to Sustain Universal Health Coverage: Society President(Apr.19)
MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official(Apr.19)
Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup(Apr.19)
Astellas Sells Agensys Research Facilities to Kite(Apr.19)
US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit(Apr.19)

Most Read

1.
AZ’s PD-L1 Inhibitor Durvalumab Up for M...
2.
PhRMA Chief Warns of Serious Implication...
3.
Pricing OK’ed for Dupixent, Tecentriq, L...
4.
Chuikyo Payer Rep Questions New Premium ...
5.
MHLW to Issue Optimal Use Guidelines for...
1.
AZ’s PD-L1 Inhibitor Durvalumab Up for M...
2.
Single Generic Pricing Rule Will Acceler...
3.
Opdivo Faces 23.8% Price Cut as Slew of ...
4.
Lilly Japan Sales Up 7% in 2017, Upbeat ...
5.
MHLW Health Policy Chief Questions Volum...

News Calendar

  • Corporate Profile|
  • Site Policy|
  • Privacy Policy|
  • Terms Of Use|
  • Link Policy|
  • Site Map|
  • Inquiry|
  • FAQ|
Jiho, Inc. is the sole copyright owner of all documents, images, and photographs on this website.
Any modification, reproduction, or use of any or all documents, images, and photographs on this website
by any unauthorized party is strictly prohibited.
Copyright (C) JIHO,Inc.